Advances in oral immunomodulating therapies in relapsing multiple sclerosis

@article{Derfuss2020AdvancesIO,
  title={Advances in oral immunomodulating therapies in relapsing multiple sclerosis},
  author={Tobias Derfuss and Matthias Mehling and Athina Papadopoulou and Amit Bar-Or and Jeffrey A. Cohen and Ludwig Kappos},
  journal={The Lancet Neurology},
  year={2020},
  volume={19},
  pages={336-347}
}
BACKGROUND Oral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action. These distinct mechanisms of action allow better adaption of treatments according to individual… 
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
TLDR
Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.
Ponesimod for the treatment of relapsing multiple sclerosis
TLDR
It is believed that ponesimod has little chance of becoming a leading treatment for RMS due to the availability of many alternative options and the timing of market access, but given its favorable risk-benefit and convenience profile, it might become a leading option among S1P receptor modulators used for R MS.
Ozanimod in relapsing forms of multiple sclerosis: a profile of its use
TLDR
In two randomised, double-blind, phase 3 clinical trials, once-daily oral ozanimod significantly reduced annualised relapse rates and MRI lesion accumulation compared with once-weekly intramuscular interferon β-1a 30 µg.
Treatment of multiple sclerosis during the covid-19 pandemic
TLDR
Care should be taken to take a proactive approach to MS treatment and focus on the patient at all stages of the disease, in order to minimize its aftereffects and maximize the quality of life.
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
TLDR
Ponesimod was superior to teriflunomide on relapse rate reduction, fatigue, brain volume loss, and no evidence of disease activity on magnetic resonance imaging activity, and time to 12-week and 24-week confirmed disability accumulation.
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis
TLDR
Electrophysiological experiments revealed that ozanimod was able to dampen the EAE glutamatergic synaptic alterations, through attenuation of local inflammatory response driven by activated microglia and infiltrating T cells, the main CNS-cellular players of EAE synaptopathy.
Stem Cell Therapies for Progressive Multiple Sclerosis
TLDR
The current state of preclinical and clinical evidence supporting the use of stem cells in treating PMS is explored and prospective hurdles impeding their translation into revolutionary regenerative medicines are discussed.
Usage trend of oral drugs for multiple sclerosis patients in Argentina.
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges
TLDR
To facilitate the availability of new agents in ped-MS, a different approach based on pharmacokinetic/pharmacodynamic studies to yield information on optimal doses and implementation of obligatory registries to obtain information on safety as primary endpoint is encouraged.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions
TLDR
Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile, and in follow-up studies with continuous fingolIMod, treatment showed sustained efficacy while being well tolerated.
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
TLDR
Fingolimod showed statistically significant superior efficacy in comparison to iDMT regarding annualized relapse rate, time-to-relapse and likelihood of relapse, and real-life evidence in German RRMS outpatients can quantitatively support clinical decision finding processes if iD MT therapy fails in RRMS.
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
TLDR
Clinical utility of S1P1R modulation for treatment of various immune-mediated disorders is suggested and ponesimod is currently in phase III clinical development to assess efficacy and safety in relapsing multiple sclerosis.
Potential mechanisms of action related to the efficacy and safety of cladribine.
TLDR
Cladribine appears to lead to re-establishment of immune-tolerance that produces long-term control of MS, and is based on knowledge about the biology of cladribine, basic immunology and the effects of other high-efficacy B and T cell depleting agents that exhibit stereotyped repopulation behaviours.
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
TLDR
Development of disease-modifying agents in MS continues to be successful, but treatment algorithms need to take new developments into account.
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
TLDR
Results from animal experiments modelling the immune activation implicated in MS demonstrate reductions in disease symptoms with teriflunomide treatment, accompanied by reduced central nervous system lymphocyte infiltration, reduced axonal loss, and preserved neurological functioning, demonstrating how terifnomide acts as a selective immune therapy for patients with MS.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
TLDR
The effect of fingolimod on relapse frequency was superior to teriflunomide and dimethyl fumarate and the effect of the three oral therapies on disability outcomes was similar during the initial 2.5 years on treatment.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
TLDR
Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo and there was no significant effect of trial group on the change from baseline in the EDSS score.
...
1
2
3
4
5
...